Last updated: March 1, 2026
What is the drug associated with NDC: 00480-8707?
The National Drug Code (NDC) 00480-8707 corresponds to Fasenra (benralizumab). It is a monoclonal antibody indicated for severe eosinophilic asthma and certain other eosinophil-driven conditions. The drug is marketed by AstraZeneca.
Market Landscape
Therapeutic Area and Competition
Fasenra targets eosinophilic asthma by depleting eosinophils through interleukin-5 receptor alpha (IL-5Rα) inhibition. It competes primarily with drugs such as:
- Nucala (mepolizumab) by GlaxoSmithKline
- Cinqair (reslizumab) by Regeneron/Sanofi
- Dupixent (dupilumab) by Regeneron/Sanofi (broader eosinophil-driven indications)
Market Size and Growth
The global asthma market exceeds USD 8 billion, with eosinophilic asthma accounting for approximately 30% of cases. The monoclonal antibody segment, including Fasenra, displays compound annual growth rate (CAGR) of around 10% from 2022 to 2027.
Key Drivers
- Increasing asthma prevalence
- Adoption of biologic therapies in severe cases
- Growing awareness and diagnosis of eosinophilic phenotypes
- Expanding indications, including eosinophilic chronic obstructive pulmonary disease (COPD)
Key Barriers
- High treatment costs
- Stringent reimbursement policies
- Need for specialized administration settings
- Patent landscape and biosimilar development
Current Pricing and Reimbursement Landscape
List Price
As of Q1 2023, the average wholesale price (AWP) for Fasenra is approximately $36,000 to $38,000 per year per patient, depending on dosing and packaging configurations. This price is comparable to competitors:
| Drug |
Approximate Annual Cost |
Administration Route |
Induction Indications |
| Fasenra |
$36,000 - $38,000 |
Subcutaneous injection |
Severe eosinophilic asthma |
| Nucala |
$36,500 |
Subcutaneous injection |
Severe eosinophilic asthma |
| Cinqair |
$38,000 |
Intravenous infusion |
Severe eosinophilic asthma |
| Dupixent |
$30,000 - $40,000 |
Subcutaneous |
Atopic dermatitis, asthma, nasal polyps |
Reimbursement Trends
Insurance adoption aligns with the significant burden of disease and positive clinical outcomes. Coverage policies favor biologic options for severe eosinophilic asthma, with prior authorization often required.
Price Trends
The market has seen limited price reductions over the past three years. Price inflation generally aligns with inflation rates in healthcare, but biosimilar entry could pressure pricing in future years.
Price Projections (2023-2028)
| Year |
Predicted Average Price Range |
Drivers |
Risks |
| 2023 |
$36,000 - $38,000 |
Stable with current market and approval base |
Biosimilar development, reimbursement tightening |
| 2024 |
$35,500 - $38,000 |
Slight price stabilization or modest reduction |
Biosimilar competition, patent challenges |
| 2025 |
$35,000 - $36,500 |
Potential biosimilar entry, healthcare cost controls |
New entrants, market saturation |
| 2026 |
$34,500 - $36,000 |
Biosimilar approvals increase |
Market maturation, pricing pressures |
| 2027 |
$34,000 - $35,500 |
Resistance to cost increases, cost management |
Policy changes, biosimilar proliferation |
| 2028 |
$33,500 - $35,000 |
Continued biosimilar competition |
Patent expirations, market shifts |
Based on current trends, a compounded annual decrease of approximately 3% to 4% is plausible due to biosimilar development and healthcare policy changes.
Key Market Opportunities
- Expansion into eosinophilic COPD
- Off-label use in eosinophil-driven conditions
- Geographic expansion into emerging markets with growing asthma prevalence
- Potential biosimilar development for cost pressures
Key Challenges
- Patent litigation or extension opportunities
- Slow uptake in certain healthcare settings due to high costs
- Delays or rejections in reimbursement approval
Final Summary
Fasenra remains a premium-priced biologic with a stable market share in eosinophilic asthma. Moderate price reductions are likely over the next five years due to biosimilar competition. Growth is driven by disease prevalence and the shift toward biologic therapies. Price pressures could intensify with patent expirations and biosimilar entry, warranting close monitoring of competitive dynamics.
Key Takeaways
- The current list price for Fasenra is around USD 36,000 per year.
- Market growth is driven by increased diagnosis and biologic adoption.
- Biosimilar pressure remains a primary factor influencing future pricing.
- Reimbursement remains positive but increasingly competitive.
- Future growth depends on expanding indications and geographic reach.
FAQs
1. How does the price of Fasenra compare to its competitors?
Fasenra’s annual list price ranges between USD 36,000 and USD 38,000, similar to Nucala and slightly higher than Dupixent, which varies depending on indication.
2. What are the main factors affecting Fasenra’s pricing?
Market competition, biosimilar development, patent protection, and reimbursement dynamics influence pricing.
3. How has biosimilar development impacted biologic prices in this segment?
Biosimilar entry tends to reduce biologic prices by 20-40% over time, aiming to increase access but challenging existing profit margins.
4. What are the primary growth opportunities for Fasenra?
Expansion into COPD, new geographical markets, and broader eosinophil-related diseases.
5. What are the main barriers to further price increases?
Patent expirations, biosimilar competition, and intensified healthcare cost controls.
References
- AstraZeneca. (2023). Fasenra (benralizumab) product information. Retrieved from AstraZeneca official site.
- IQVIA. (2023). Global biologics market report. Retrieved from IQVIA insights.
- EvaluatePharma. (2023). Biologic market forecast. Retrieved from EvaluatePharma.
- U.S. Food & Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
- Centers for Disease Control and Prevention. (2022). Asthma statistics and prevalence.
